Hughes Financial Services
CLDX icon

Hughes Financial Services’s Celldex Therapeutics CLDX Stock Holding History

Hughes Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30 Hold
1
– – ﹤0.01% 1847
2026
Q2 		$37 Hold
1
– – ﹤0.01% 1659
2026
Q1 		$32 Buy
+1
New +$27 ﹤0.01% 1545
2025
Q2 		– Sell
-24
Closed -$404 – 1081
2025
Q1 		$404 Buy
+24
New +$536 ﹤0.01% 1011

Other funds holding CLDX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Hughes Financial Services's CLDX Position: Q3 2026 in Review

Hughes Financial Services held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 1 share worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

Hughes Financial Services first reported a position in CLDX in Q1 2025 and has held it in 4 quarters since. The position peaked at $404 in Q1 2025. 83 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Hughes Financial Services held 1 share of Celldex Therapeutics worth $30 as of Q3 2026.
  • Hughes Financial Services left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q3 2026, its #1847 holding.
  • Hughes Financial Services first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Hughes Financial Services's Celldex Therapeutics position peaked at $404 in Q1 2025.
  • 83 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Hughes Financial Services's 13F filing for Q3 2026, filed 30 Oct 2026.